sumatriptan succinate · Teva Branded Pharm · NDA 202278
Zecuity
Earliest generic entry, as listed
8 Oct 2032
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 9327114.
Listed patents · 9 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9327114 | product, use U-1328 | 8 Oct 2032 |
| US 8983594 | product, use U-1328 | 19 Nov 2030 |
| US 8366600 | use U-1327 | 21 Apr 2029 |
| US 9272137 | product | 7 Sep 2027 |
| US 7973058 | use U-1328 | 12 Apr 2027 |
| US 8155737 | use U-1328 | 12 Apr 2027 |
| US 8470853 | use U-1328 | 12 Apr 2027 |
| US 8597272 | product | 12 Apr 2027 |
| US 9427578 | product, use U-1328 | 12 Apr 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 202278 · 001 · RLD · discontinued | system, iontophoresis | EQ 6.5MG BASE/4HR | 8 Oct 2032 |